Daiichi Sankyo to present new lung cancer research at WCLC 2025
Daiichi Sankyo will present new clinical research across its DXd antibody drug conjugate (ADC) portfolio in lung cancer at the IASLC 2025 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (#WCLC25). Data at WCLC will showcase the company’s progress towards creating new standards of care for patients with lung cancer, including a late-breaking oral presentation featuring the primary analysis from the dose optimization and dose expansion parts of the IDeate-Lung01 phase II trial (OA06.03) of ifinatamab deruxtecan (I-DXd) in patients with pretreated extensive-stage small cell lung cancer (ES-SCLC). Interim data from the dose optimization part of the trial was previously presented at 2024 WCLC.
“The late-breaking data at WCLC continues to demonstrate the potential of ifinatamab deruxtecan to become a first-in-class B7-H3 directed antibody drug conjugate for patients with pretreated extensive-stage small cell lung cancer, where treatment options following platinum-based chemotherapies are limited,” said Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo. “These data along with other important updates across our portfolio continue to demonstrate how our DXd antibody drug conjugate technology is being leveraged to create new medicines for patients with cancer.”
Additional data updates at WCLC include an oral presentation featuring a retrospective analysis of the intracranial efficacy of Datroway (datopotamab deruxtecan) or docetaxel in patients with non-small cell lung cancer (NSCLC) and baseline brain metastases in the TROPION-Lung01 phase III trial (0A10.01), and a poster presentation of the final results of the DESTINY-Lung05 phase II trial (P2.10.12) of Enhertu (trastuzumab deruxtecan) in patients from China with previously treated HER2 mutant NSCLC.
Trials-in-Progress Across DXd ADC Portfolio
Several trials-in-progress poster presentations at WCLC further highlight the Daiichi Sankyo R&D strategy of continuing to expand the DXd ADC portfolio to address a broad spectrum of unmet needs for patients with lung cancer, including the DESTINY-Lung06 phase III trial evaluating the efficacy and safety of Enhertu plus pembrolizumab versus platinum-based chemotherapy plus pembrolizumab as a first-line treatment strategy for patients with HER2 overexpressing, PD-L1 TPS.
Other early phase trials evaluating additional treatment strategies in lung cancer include the KEYMAKER-U01 substudy 01G phaseII2 trial evaluating patritumab deruxtecan (HER3-DXd) in combination with pembrolizumab with or without platinum chemotherapy in patients with previously untreated stage 4 NSCLC, and a phase 1b/2 trial evaluating ifinatamab deruxtecan and gocatamig, a DLL3 targeted T-cell engager, in patients with relapsed or refractory ES-SCLC will be highlighted.
Investor Briefing Following WCLC Daiichi Sankyo will hold a virtual conference call for investors on Wednesday, September 17, 2025 from 7:00 to 8:15 pm EDT / Thursday, September 18 from 8:00 to 9:15 am JST. Executives from Daiichi Sankyo will provide an overview of the late-breaking WCLC data and clinical development plan for ifinatamab deruxtecan.
WCLC Presentation Title Presenter i. Ifinatamab deruxtecan (I-DXd) Abstract Presentation (CEST) Ifinatamab deruxtecan (I-DXd) in extensive-stage small cell lung cancer: primary analysis of the phase II IDeate-Lung01 study . ii M. Ahn OA06.03 Oral Presentation Sunday, September 7 4:45 – 6:00 pm A phase 1b/II study of gocatamig and ifinatamab deruxtecan for relapsed or refractory extensive-stage small cell lung cancer. iii. P. Rocha P3.18.73 Poster Presentation Tuesday, September 9 10:00 – 11:30 am ENHERTU (trastuzumab deruxtecan; T-DXd) Trastuzumab deruxtecan in patients from China with pretreated HER2 mutant NSCLC: iv. final results from the DESTINY-Lung05 study B. Wang P2.10.12 Poster Session Monday, September 8 10:30 am – 12:00 pm Trastuzumab deruxtecan + pembrolizumab as first-line treatment in HER2 overexpressing, PD-L1 TPS. v. Real world assessment of TROP2-NMR by quantitative continuous scoring (QCS) in non-small cell lung carcinoma (NSCLC) vi. Patritumab Deruxtecan (HER3-DXd) F. Lopez Rios OA09.03 Oral Presentation Monday, September 8 3:30 – 4:45 pm KEYMAKER-U01 substudy 01G: pembrolizumab + patritumab deruxtecan ± chemotherapy in previously untreated stage IV NSCLC V. Velcheti P3.18.28 Poster Presentation Tuesday, September 9 10:00 – 11:30 am
